1,082 reports of this reaction
3.2% of all REGORAFENIB reports
#5 most reported adverse reaction
DECREASED APPETITE is the #5 most commonly reported adverse reaction for REGORAFENIB, manufactured by Bayer HealthCare Pharmaceuticals Inc.. There are 1,082 FDA adverse event reports linking REGORAFENIB to DECREASED APPETITE. This represents approximately 3.2% of all 34,211 adverse event reports for this drug.
Patients taking REGORAFENIB who experience decreased appetite should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DECREASED APPETITE is moderately reported among REGORAFENIB users, representing a notable but not dominant share of adverse events.
In addition to decreased appetite, the following adverse reactions have been reported for REGORAFENIB:
The following drugs have also been linked to decreased appetite in FDA adverse event reports:
DECREASED APPETITE has been reported as an adverse event in 1,082 FDA reports for REGORAFENIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
DECREASED APPETITE accounts for approximately 3.2% of all adverse event reports for REGORAFENIB, making it a notable side effect.
If you experience decreased appetite while taking REGORAFENIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.